BGPT: Paper Review: A novel mutation expands the genetic and clinical spectrum of MYH7-related myopathies

Explore by Goal

Quick Explanation Copied

Core finding: The paper reports a de novo MYH7 missense mutation p.Leu1597Arg in two unrelated probands, with high clinical + histopathologic divergence (Case 1: multi-minicore; Case 2: CFTD) despite the same variant.

Long Explanation

Paper Review (Visual-first): MYH7 p.Leu1597Arg expands spectrum & diversifies phenotype

Neuromuscular Disorders • DOI: 10.1016/j.nmd.2013.02.009

1) What the paper does (evidence-driven)

Reports a novel heterozygous MYH7 mutation p.Leu1597Arg (c.4790T>G) found de novo in two unrelated probands with congenital myopathy phenotypes.
Shows divergent clinical course and divergent muscle pathology: Case 1 (distal weakness + prominent contractures; biopsy consistent with multi-minicore); Case 2 (axial myopathy; biopsy consistent with congenital fiber type disproportion).
Argues this supports MYH7’s involvement in a broader congenital myopathy landscape and warns against relying on clinical/histologic labels alone.

2) Visualize the two probands side-by-side (only from what’s reported)

Careful epistemic note: The flags above are intentionally conservative (0/1) and only reflect whether the narrative explicitly states the feature (e.g., cardiac investigations described as normal). If a feature is not explicitly described for a case, it is treated as 0 rather than assumed.

3) Mutation-level context: where p.Leu1597Arg sits and why it matters

The paper states the variant is located within the light meromyosin (LMM) region and compares this to other skeletal MYH7 myopathy mutations.
Mechanistic claim present in the paper: the LMM region mediates protein-protein interactions between myosin and other myosin-binding proteins (used to motivate causality).

4) What evidence supports causality in this paper (and what it does not)

Evidence the paper uses

Evidence type	What’s stated	Caveat / skeptical check
Rarity / database absence	Case 1 variant absent from NCBI dbSNP, 1000 Genomes, Exome Variant Server; Case 2 variant described as absent in large control datasets (via discussion wording).	Population absence does not prove pathogenicity; it can also reflect under-sampling, sequencing/pipeline differences, or misclassification of true phenotypes. (This limitation follows general variant interpretation principles; the paper itself does not quantify effect sizes.)
De novo occurrence	The mutation is de novo in both probands (supported by parental DNA testing for both cases).	Still correlational: without functional assays or additional segregation in relatives, de novo supports but doesn’t fully establish mechanism.
Biological plausibility	Variant lies in LMM region, implicated in myosin–binding protein interactions.	The paper does not report direct measurements of altered protein interactions, ATPase kinetics, or sarcomere assembly in patient material.

5) Visual compare: histopathology divergence (multi-minicore vs CFTD)

Important constraint: Because this is a two-proband report, “expands spectrum” is supported as a case-based expansion rather than a statistically estimated population effect.

6) Strengthening/weakening considerations (skeptical critique)

Strengths

Genetic evidence is tightly linked to phenotype via de novo status in both cases and rarity in population datasets.
High-contrast phenotypic divergence makes the core message (same variant → different phenotypes/pathology) hard to dismiss as minor variability.

Key limitations / unknowns

Sample size = 2. The paper can expand candidate space, but it cannot quantify penetrance, true spectrum frequencies, or distribution of histology types.
No functional validation of p.Leu1597Arg (e.g., altered protein interactions, sarcomere assembly defects, contractility/ATPase changes) is reported in the provided text. The causality argument relies on genetics + plausibility rather than assays.
Potential genetic modifiers are not systematically ruled out. For Case 2, additional heterozygous variants (RYR1, COL6A3, TTN) are reported but are stated to be present in a healthy parent; this is reassuring but doesn’t fully exclude modifier effects (e.g., additive variants, variable penetrance, mosaicism not assessed).

7) Contextualizing with other MYH7 variability papers (to calibrate “spectrum expansion”)

MYH7-related disease variability is not unprecedented: other case/family reports document that MYH7 mutations can produce distinct skeletal muscle patterns and sometimes variable cardiac involvement. For example, a 2014 report identifies a novel MYH7 variant p.Leu1723Pro causing autosomal dominant eccentric core disease.
Similarly, broader clinical variability is also described in MYH7 contexts beyond Laing distal myopathy (e.g., MYH7 p.K1729del transition in a cohort with diverse profiles).
Across cardiology cohorts, MYH7 mutations can associate with characteristic phenotype patterns (e.g., younger diagnosis and greater hypertrophy in hypertrophic cardiomyopathy), illustrating that MYH7 can be diagnostically relevant in multiple organ contexts.

8) Minimal data visualization from the paper’s extracted structure

What would change my confidence? If additional unrelated MYH7 p.Leu1597Arg carriers show non-overlapping phenotypes (or if other genetic variants segregate more tightly in extended relatives), the current attribution could weaken. Conversely, if expanded cohorts consistently show the same variant with similar multi-system/biopsy patterns, causality would strengthen (even without full mechanism).

9) Buttons for bespoke follow-up Author Reviews

Feedback:

Updated: March 27, 2026